Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277640 | 0.90 | THRB (0.42) | THRBLMNA | |
| SCHEMBL3083973 | 0.89 | THRB (0.36) | THRBLMNA | |
| SCHEMBL17807890 | 0.89 | THRB (0.36) | THRBLMNA | |
| SCHEMBL11760550 | 0.88 | THRB (0.40) | THRBLMNA | |
| SCHEMBL880513 | 0.84 | THRB (0.33) | THRBLMNA | |
| SCHEMBL17850558 | 0.84 | LMNA (0.38) | THRBLMNA | |
| SCHEMBL9624071 | 0.83 | HSD17B10 (0.48) | THRBLMNA | |
| SCHEMBL618028 | 0.83 | THRB (0.36) | THRBLMNA | |
| SCHEMBL23581082 | 0.79 | THRB (0.38) | THRBLMNA | |
| SCHEMBL8143953 | 0.79 | TSHR (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3159335-B1 | NOVEL HETEROCYCLIC COMPOUND | DAE WOONG PHARMA (KR) | 2020-04-29 | — | — | EP | claimed |
| US-11028101-B2 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD (AU) | 2021-06-08 | — | — | US | disclosed |
| EP-3426635-B1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2021-05-05 | — | — | EP | disclosed |
| US-20200087320-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-03-19 | — | — | US | disclosed |
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190092786-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2019-03-28 | — | — | US | disclosed |
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017153519-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| US-5221608-A | Adding a polymerase and an isopsoralen compound to a mixture of nucleic acid and amplification reagents, and exposing to ultraviolet radiation to form isopsoralen monoadduct which inhibits polymerase | STERITECH, INC. | 1993-06-22 | — | — | US | disclosed |
| US-5184020-A | For treating photoreactive compounds | STERITECH, INC. | 1993-02-02 | — | — | US | disclosed |
| US-5139940-A | Isopsoralen derives; complex with nucleic acids | STERITECH, INC. | 1992-08-18 | — | — | US | disclosed |
| EP-0497921-A1 | ACTIVATION COMPOUNDS AND METHODS FOR NUCLEIC ACID STERILIZATION | ISAACS, Stephen T. (US) | 1992-08-12 | — | — | EP | disclosed |
| WO-1991006665-A1 | ACTIVATION COMPOUNDS AND METHODS FOR NUCLEIC ACID STERILIZATION | ISAACS STEPHEN T (US) | 1991-05-16 | — | — | WO | disclosed |
| EP-0377967-A2 | 9-Aza-3-(oxa/thia)-bicyclo[3,2,1]nonane derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1990-07-18 | — | — | EP | disclosed |
| US-4585859-A | ANTITUMOR AGENTS | SRI INTERNATIONAL (US) | 1986-04-29 | — | — | US | disclosed |
| EP-0128670-A1 | 4-Demethoxy-3'-deamino-3'(4-morpholinyl) derivatives of anthracycline anticancer antibiotics | ADRIA LABORATORIES, INC. (US) | 1984-12-19 | — | — | EP | disclosed |
| US-4464529-A | ANTITUMOR AGENTS | SRI INTERNATIONAL (US) | 1984-08-07 | — | — | US | disclosed |
| US-3957997-A | Anticoccidial complexes of 4,4'-dinitrocarbanilides | MERCK & CO., INC. (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087320-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | HBB, HBZ, HBG2 | THRB 158/4885LMNA 1700/4885 |
| US-11028101-B2 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | HBB, HBZ, HBG2 | THRB 162/4885LMNA 1661/4885 |
| US-20190092786-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | HBB, HBG2, HBZ | THRB 170/4885LMNA 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.